Overview This two-day hybrid meeting, held on October 22-23 in Washington, D.C., at the Bloomberg Center brought together a number of key stakeholders working on drugresistant TB (DR-TB) to discuss pre-approval access (a term that encompasses numerous other terms, including compassionate use) to new TB drugs for people living with DR-TB who have limited treatment options. The meeting was sponsored by the Office of the Provost of Johns Hopkins University and Unitaid and co-convened by members of The BETTER (Building Experience Treating TB with Expanded Resistance) Project. It was part one of a two-part meeting on closing the global health research-toaccess gap (part two will be held in spring of 2026). This meeting report summarizes the key discussions and action items from the sessions. The sessions were recorded, and presentations are available on request. The group will also be drafting a paper for publication in a peer-reviewed journal (tentatively titled “Compassionate Use Support Programs for Drug-Resistant Tuberculosis: A Model for Accelerating Access Across the Drug Development Spectrum”). The meeting agenda and participant list are available in the annex to this report.